{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:41:49Z","timestamp":1778942509628,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.10.062","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T21:09:56Z","timestamp":1604005796000},"page":"7916-7927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The respiratory syncytial virus fusion protein-specific B cell receptor repertoire reshaped by post-fusion subunit vaccination"],"prefix":"10.1016","volume":"38","author":[{"given":"Gerald","family":"Schneikart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Tavarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Sammicheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Torricelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Guidotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-5788","authenticated-orcid":false,"given":"Emanuele","family":"Andreano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Buricchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"D'Oro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8652-6534","authenticated-orcid":false,"given":"Oretta","family":"Finco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monia","family":"Bardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl A","key":"10.1016\/j.vaccine.2020.10.062_b0005","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S1526-0542(04)90023-1","article-title":"Respiratory syncytial virus: the virus, the disease and the immune response","volume":"5","author":"Ogra","year":"2004","journal-title":"Paediatr Respir Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.062_b0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/187152612800100099","article-title":"The burgeoning burden of respiratory syncytial virus among children","volume":"12","author":"Hall","year":"2012","journal-title":"Infect Disord Drug Targets"},{"issue":"10098","key":"10.1016\/j.vaccine.2020.10.062_b0015","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.062_b0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.062_b0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coi.2015.04.005","article-title":"Novel antigens for RSV vaccines","volume":"35","author":"Graham","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.062_b0030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.vaccine.2015.05.093","article-title":"WHO consultation on respiratory syncytial virus vaccine development report from a world health organization meeting held on 23\u201324 March 2015","volume":"34","author":"Modjarrad","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.062_b0035","first-page":"103","article-title":"Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab","volume":"317","author":"Wu","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2020.10.062_b0040","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1542\/peds.2009-2345","article-title":"From the American Academy of Pediatrics: Policy statements\u2013Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections","volume":"124","author":"Bocchini","year":"2009","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.062_b0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/archdischild-2015-308780","article-title":"Where are we with RSV prophylaxis?","volume":"101","author":"Caldwell","year":"2016","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"3","key":"10.1016\/j.vaccine.2020.10.062_b0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QCO.0000000000000161","article-title":"Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?","volume":"28","author":"Munoz","year":"2015","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.10.062_b0055","doi-asserted-by":"crossref","first-page":"B209","DOI":"10.1016\/j.vaccine.2012.11.106","article-title":"Strategic priorities for respiratory syncytial virus (RSV) vaccine development","volume":"31","author":"Anderson","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2020.10.062_b0060","doi-asserted-by":"crossref","first-page":"eaaj1879","DOI":"10.1126\/sciimmunol.aaj1879","article-title":"Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors","volume":"1","author":"Gilman","year":"2016","journal-title":"Sci Immunol"},{"issue":"6136","key":"10.1016\/j.vaccine.2020.10.062_b0065","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"7467","key":"10.1016\/j.vaccine.2020.10.062_b0070","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature12442","article-title":"Cross-neutralization of four paramyxoviruses by a human monoclonal antibody","volume":"501","author":"Corti","year":"2013","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.062_b0075","doi-asserted-by":"crossref","first-page":"e1005035","DOI":"10.1371\/journal.ppat.1005035","article-title":"Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein","volume":"11","author":"Gilman","year":"2015","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.vaccine.2020.10.062_b0080","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S1473-3099(15)00247-9","article-title":"Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial","volume":"15","author":"O'Brien","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.062_b0085","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nsmb.1723","article-title":"Structural basis of respiratory syncytial virus neutralization by motavizumab","volume":"17","author":"McLellan","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"23","key":"10.1016\/j.vaccine.2020.10.062_b0090","doi-asserted-by":"crossref","first-page":"12236","DOI":"10.1128\/JVI.01579-10","article-title":"Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F","volume":"84","author":"McLellan","year":"2010","journal-title":"J Virol"},{"issue":"23","key":"10.1016\/j.vaccine.2020.10.062_b0095","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1073\/pnas.1106536108","article-title":"Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers","volume":"108","author":"Swanson","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.vaccine.2020.10.062_b0100","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1016\/S0264-410X(03)00352-9","article-title":"Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women","volume":"21","author":"Munoz","year":"2003","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2020.10.062_b0105","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.vaccine.2019.04.011","article-title":"Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study","volume":"37","author":"Leroux-Roels","year":"2019","journal-title":"Vaccine"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2020.10.062_b0110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.molimm.2009.08.024","article-title":"The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations","volume":"47","author":"Williams","year":"2009","journal-title":"Mol Immunol"},{"issue":"14","key":"10.1016\/j.vaccine.2020.10.062_b0115","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.4155\/bio.13.145","article-title":"The Gyrolab immunoassay system: a platform for automated bioanalysis and rapid sample turnaround","volume":"5","author":"Fraley","year":"2013","journal-title":"Bioanalysis"},{"issue":"6158","key":"10.1016\/j.vaccine.2020.10.062_b0120","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"6452","key":"10.1016\/j.vaccine.2020.10.062_b0125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.vaccine.2020.10.062_b0130","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes","volume":"85","author":"McLellan","year":"2011","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.10.062_b0135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/gene.2012.12","article-title":"The immunoglobulin heavy chain locus: genetic variation, missing data, and implications for human disease","volume":"13","author":"Watson","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.vaccine.2020.10.062_b0140","doi-asserted-by":"crossref","first-page":"103","DOI":"10.12688\/f1000research.2-103.v1","article-title":"Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors","volume":"2","author":"Kepler","year":"2013","journal-title":"F1000Res"},{"key":"10.1016\/j.vaccine.2020.10.062_b0145","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fimmu.2014.00170","article-title":"Reconstructing a B-Cell clonal lineage. II. Mutation, selection, and affinity maturation","volume":"5","author":"Kepler","year":"2014","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.062_b0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0145-305X(02)00039-3","article-title":"IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains","volume":"27","author":"Lefranc","year":"2003","journal-title":"Dev Comp Immunol"},{"issue":"Database issue","key":"10.1016\/j.vaccine.2020.10.062_b0155","doi-asserted-by":"crossref","first-page":"D413","DOI":"10.1093\/nar\/gku1056","article-title":"IMGT(R), the international ImMunoGeneTics information system(R) 25 years on","volume":"43","author":"Lefranc","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"10.1016\/j.vaccine.2020.10.062_b0160","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1093\/nar\/gks457","article-title":"Quantifying selection in high-throughput Immunoglobulin sequencing data sets","volume":"40","author":"Yaari","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2020.10.062_b0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fimmu.2013.00358","article-title":"Models of somatic hypermutation targeting and substitution based on synonymous mutations from high-throughput immunoglobulin sequencing data","volume":"4","author":"Yaari","year":"2013","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.vaccine.2020.10.062_b0170","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/bioinformatics\/btm147","article-title":"iHMMune-align: hidden Markov model-based alignment and identification of germline genes in rearranged immunoglobulin gene sequences","volume":"23","author":"Gaeta","year":"2007","journal-title":"Bioinformatics"},{"key":"10.1016\/j.vaccine.2020.10.062_b0175","doi-asserted-by":"crossref","unstructured":"Schneikart G, Tavarini S, Sammicheli C, Torricelli G, Guidotti S, D\u2019Oro U, Finco O, and Bardelli M. Dataset of antibody variable region sequence features inferred from a respiratory syncytial virus fusion protein-specific B cell receptor repertoire induced by natural infection of a healthy adult. Data in Brief 2020 (in press).","DOI":"10.1016\/j.dib.2020.106499"},{"issue":"1676","key":"10.1016\/j.vaccine.2020.10.062_b0180","article-title":"Restricted, canonical, stereotyped and convergent immunoglobulin responses","volume":"370","author":"Henry Dunand","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.vaccine.2020.10.062_b0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","author":"Robbiani","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2020.10.062_b0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nri3802","article-title":"Memory B cells","volume":"15","author":"Kurosaki","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.062_b0195","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri3128","article-title":"Molecular programming of B cell memory","volume":"12","author":"McHeyzer-Williams","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2020.10.062_b0200","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.chom.2013.05.008","article-title":"Convergent antibody signatures in human dengue","volume":"13","author":"Parameswaran","year":"2013","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.062_b0205","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V97.4.1023","article-title":"V(H)1\u201369 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen","volume":"97","author":"Chan","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.vaccine.2020.10.062_b0210","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41591-019-0602-4","article-title":"Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV","volume":"25","author":"Ehrhardt","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.062_b0215","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chom.2014.05.013","article-title":"Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements","volume":"16","author":"Jackson","year":"2014","journal-title":"Cell Host Microbe"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:48:30Z","timestamp":1759402110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20313712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":43,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20313712"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The respiratory syncytial virus fusion protein-specific B cell receptor repertoire reshaped by post-fusion subunit vaccination","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}